In the second part of VIGILINT’s two-part series COVID-19 1 Year Later, VIGILINT Ops Analyst and blogger Colin Schilly dives into the two critical hallmarks of the pandemic. Testing and vaccines. The development and rollout of several effective vaccines in under a year offer great hope for the pandemic’s end. Sadly, that day may still… Continue reading COVID-19 ONE YEAR LATER, Part II: Testing and Vaccines
COVID-19 VACCINES FAQ JAN13
The World Health Organization (WHO) became aware of the disease known as COVID-19 on December 31, 2019. Since then, there have been 86 million confirmed cases, over 1.8 million deaths, and 355,000 deaths in the U.S. alone. After months of effort and billions of dollars spent, distribution of the first COVID-19 vaccines is underway. A… Continue reading COVID-19 Vaccines: What are the Side Effects?
Vaccine development for COVID-19 is topic number one, and our collective hope for going back to “normal” dangle on that needle. The global race to market includes pharma’s heavy hitters like Pfizer, Johnson & Johnson, AstraZeneca, and Moderna, a Cambridge, Massachusetts-based company that displayed hopeful results in Phase-1 trials and just this week received another… Continue reading COVID-19 Update: The Race for a Vaccine